WASHINGTON, June 24 On June 4, 2008, U.S. CommerceSecretary Carlos Gutierrez became the first U.S. cabinet official to visitMaxWell Biocorporation's 150,000-square-foot pharmaceutical productionfacility in Boryspil, Ukraine.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080624/NETU078LOGO )
Gutierrez joined the founder, President and CEO of MaxWell BiocorporationDr. Ken Alibek to officially open MaxWell's new pharmaceutical developmentcenter and quality control laboratory, co-located with the largerpharmaceutical production facility that opened officially on March 26, 2008.
Gutierrez and Alibek were joined at the ribbon-cutting ceremony by U.S.Ambassador to Ukraine William Taylor, President of the Academy of MedicalSciences of Ukraine Olexander F. Vozianov, and representatives of leadingpharmaceutical companies in Ukraine.
Gutierrez visited MaxWell Biocorporation's Boryspil facility during hisofficial trip to Ukraine on June 4-5. The U.S. Commerce Secretary alsoaddressed the American Chamber of Commerce in Kyiv, held a roundtablediscussion with U.S. business leaders, and met with Ukraine's PresidentYushchenko, Prime Minister Tymoshenko, and other senior Ukrainian officials topromote greater bilateral trade and investment.
According to the U.S. Department of Commerce, bilateral trade between theUnited States and Ukraine exceeded $2.5 billion in 2007, with U.S. exportsgrowing by more than 77 percent. Ukraine's pharmaceutical market alone grew anestimated 22% in 2007, with 12% growth predicted for 2008.
Earlier this year, the United States and Ukraine concluded a Trade andInvestment Cooperation Agreement, which establishes a framework for a deeperdialogue on trade and investment.
Photos of the event may be accessed on the MaxWell corporate website(http://www.max-well.com/eng/company_news.php?news_id=250) and on the U.S.Commerce Department home page( http://www.commerce.gov/NewsRoom/TopNews/Images/PROD01_006605 ).
MaxWell Biocorporation is a U.S.-based, privately-held internationalmedical and pharmaceutical company with wholly owned subsidiaries andaffiliates in the United States and Ukraine dedicated to increasing lifeexpectancy and improving the quality of life of people in Ukraine and otherunderserved emerging healthcare markets in the former Soviet Union. MaxWelltargets oncological, cardiological, chronic infectious and autoimmunedisorders and diseases through the development, production, and introductioninto clinical practice of sophisticated, high quality, and affordableoff-patent generic biopharmaceutical and chemopharmaceutical medicines and thelatest diagnostic and therapeutic methods. MaxWell = "Maximum Wellness.""We Help You Live Longer" Contact: Alex Meerovich A.Meerovich@max-well.com 202-454-3403
SOURCE MaxWell Biocorporation